Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Solomon, Scott R  [Clear All Filters]
Journal Article
Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, H Holland K. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020;4(19):4812-4821.
Solomon SR, Solh M, Zhang X, Brown S, Jackson KC, H Holland K, Morris LE, Bashey A. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020;4(15):3669-3676.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, et al. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncol. 2024.
Solomon SR, St Martin A, Zhang M-J, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LAnn, Brunstein C, Chhabra S, Perez MAngel Diaz, et al. Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
Solomon SR, Solh M, Morris LE, H Holland K, Bashey A. Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:9736564.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022.
Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022.
Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022.
Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, H Holland K, Solh MM, Bashey A. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4(20):5311-5321.